VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 3, 2007) - Pyng Medical Corp. (TSX VENTURE:PYT) has announced their submission for registration of the FAST1(TM) Intraosseous Infusion System with the Mexican Ministry of Health. Medstent, S.A. de C.V. of Mexico City is the authorized representative for Pyng within Mexico.
"Entry into the Mexico market is part of Pyng's ongoing focus on expanding into international markets," said David Christie, President and Chief Executive Officer. "We know from our experience and success in other international launches, the FAST1(TM) will be well received."
"We are excited with the potential in the public and private healthcare markets in Mexico," says Carlos Vonderwalde, Partner of Medstent, "With our strong sales force and distribution capability, there will be considerable uptake on the FAST1(TM) as soon as we receive Ministry authorization."
About Pyng Medical Corp.
Pyng Medical Corp. is a world leader in intraosseous infusion with its proprietary award-winning FAST1(TM) Intraosseous Infusion System, the only device able to provide rapid sternal access and delivery of life saving fluids and drugs to the heart of critically injured patients in seconds. The FAST1(TM) is used extensively by the U.S. Department of Defense and by Emergency Medical Services around the globe.
Medstent has been serving the Mexican medical community since 1995 and from the start has been committed to supplying top quality service and products through a synergy of service, products and people. As a long-term provider, Medstent has built a highly trained sales force of product specialists/salespeople and a network of four sub-distributors which are strategically located throughout the Mexican Republic. The company has successfully built strong relationships with clients in both public and private markets.
Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.
FOR FURTHER INFORMATION PLEASE CONTACT:
Pyng Medical Corp.